Low-frequency KRAS mutations are prevalent in lung adenocarcinomas.
Low-frequency KRAS mutations are prevalent in lung adenocarcinomas.
复制标题
DOI：
10.2217/pme.14.69
复制
发表时间：
2015-03
影响因子：
2.3
通讯作者：
Parsons BL
中科院分区：
文献类型：
--
作者：
Myers MB;McKim KL;Meng F;Parsons BL
This study quantified low-frequency KRAS mutations in normal lung and lung adenocarcinomas, to understand their potential significance in the development of acquired resistance to EGFR-targeted therapies. Allele-specific Competitive Blocker-PCR was used to quantify KRAS codon 12 GAT (G12D) and GTT (G12V) mutation in 19 normal lung and 21 lung adenocarcinoma samples. Lung adenocarcinomas had KRAS codon 12 GAT and GTT geometric mean mutant fractions of 1.94 × 10−4 and 1.16 × 10−3, respectively. For 76.2% of lung adenocarcinomas, the level of KRAS mutation was greater than the upper 95% confidence interval of that in normal lung. KRAS mutant tumor subpopulations, not detectable by DNA sequencing, may drive resistance to EGFR blockade in lung adenocarcinoma patients.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-10-2277
发表时间：
2011-03-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Arcila ME;Oxnard GR;Nafa K;Riely GJ;Solomon SB;Zakowski MF;Kris MG;Pao W;Miller VA;Ladanyi M
通讯作者：
Ladanyi M
影响因子：
45.3
作者：
Eberhard, DA;Johnson, BE;Hillan, KJ
通讯作者：
Hillan, KJ
影响因子：
64.5
作者：
Govindan R;Ding L;Griffith M;Subramanian J;Dees ND;Kanchi KL;Maher CA;Fulton R;Fulton L;Wallis J;Chen K;Walker J;McDonald S;Bose R;Ornitz D;Xiong D;You M;Dooling DJ;Watson M;Mardis ER;Wilson RK
通讯作者：
Wilson RK
影响因子：
11.2
作者：
Arena, Sabrina;Isella, Claudio;Bardelli, Alberto
通讯作者：
Bardelli, Alberto
影响因子：
16.6
作者：
Gerstung, Moritz;Beisel, Christian;Beerenwinkel, Niko
通讯作者：
Beerenwinkel, Niko